MET and melanoma: In particular, MEK162, a MEK1/2-inhibitor, was recently proposed as the first type of target therapy to show activity in patients with NRAS-dependent melanoma and, in addition, individuals with similar molecular characteristics were found to be uniquely sensitive to CMET inhibition, thus providing a new rationale for therapeutic targeting of CMET in this patient cohort [48, 49].